Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Helen M. Colhoun et al.|The Lancet|2019Cited by 3.1k
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Helen M. Colhoun et al.|The Lancet|2019Cited by 640
Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF RegistryShinya Goto, Dan Atar, Harry Gibbs et al.|Journal of the American Heart Association|2019Cited by 55